Commerzbank Aktiengesellschaft FI Takes $206,000 Position in ResMed Inc. (RMD)
Commerzbank Aktiengesellschaft FI bought a new stake in shares of ResMed Inc. (NYSE:RMD) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 2,434 shares of the medical equipment provider’s stock, valued at approximately $206,000.
A number of other hedge funds have also bought and sold shares of RMD. Dimensional Fund Advisors LP increased its holdings in ResMed by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 379,317 shares of the medical equipment provider’s stock worth $29,535,000 after purchasing an additional 2,530 shares during the last quarter. Stifel Financial Corp increased its holdings in ResMed by 55.4% during the 2nd quarter. Stifel Financial Corp now owns 9,033 shares of the medical equipment provider’s stock worth $703,000 after purchasing an additional 3,219 shares during the last quarter. Janus Henderson Group PLC increased its holdings in ResMed by 1,205.7% during the 2nd quarter. Janus Henderson Group PLC now owns 222,648 shares of the medical equipment provider’s stock worth $17,337,000 after purchasing an additional 205,596 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in ResMed by 1.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 209,022 shares of the medical equipment provider’s stock worth $16,277,000 after purchasing an additional 3,728 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its holdings in ResMed by 2.9% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 47,056 shares of the medical equipment provider’s stock worth $3,665,000 after purchasing an additional 1,306 shares during the last quarter. Institutional investors own 61.41% of the company’s stock.
In other news, CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $85.36, for a total value of $106,700.00. Following the completion of the sale, the chief financial officer now directly owns 79,572 shares in the company, valued at approximately $6,792,265.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John P. Wareham sold 25,934 shares of the business’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $102.25, for a total value of $2,651,751.50. Following the completion of the sale, the director now owns 38,934 shares of the company’s stock, valued at $3,981,001.50. The disclosure for this sale can be found here. Insiders sold a total of 49,802 shares of company stock valued at $4,824,727 over the last quarter. Company insiders own 1.77% of the company’s stock.
ResMed (NYSE:RMD) last issued its quarterly earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.22. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The business had revenue of $601.27 million during the quarter, compared to the consensus estimate of $583.77 million. During the same period in the previous year, the business earned $0.73 EPS. The business’s quarterly revenue was up 13.4% on a year-over-year basis. sell-side analysts expect that ResMed Inc. will post 3.34 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, February 8th will be issued a $0.35 dividend. The ex-dividend date is Wednesday, February 7th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.57%. ResMed’s dividend payout ratio (DPR) is 70.00%.
RMD has been the topic of several analyst reports. Zacks Investment Research upgraded ResMed from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Thursday, October 12th. Northland Securities restated a “sell” rating and set a $55.00 price objective on shares of ResMed in a report on Friday, October 27th. BMO Capital Markets lifted their price objective on ResMed to $82.00 and gave the stock a “market perform” rating in a report on Tuesday, December 12th. JPMorgan Chase & Co. lifted their price objective on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a report on Monday, October 30th. Finally, Needham & Company LLC restated a “sell” rating on shares of ResMed in a report on Friday, October 27th. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. ResMed presently has a consensus rating of “Hold” and an average target price of $76.00.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/09/commerzbank-aktiengesellschaft-fi-takes-206000-position-in-resmed-inc-rmd.html.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.